Viewing Study NCT04553692

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:51 PM
Ignite Modification Date: 2026-01-20 @ 10:24 PM
Study NCT ID: NCT04553692
Status: TERMINATED
Last Update Posted: 2025-03-28
First Post: 2020-09-04
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Sponsor: IGM Biosciences, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Solid Tumor View
None Colorectal Cancer View
None Non Hodgkin Lymphoma View
None Sarcoma View
None Chondrosarcoma View
None Small Lymphocytic Lymphoma View
None Chronic Lymphocytic Leukemia View
None Acute Myeloid Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Relapsed and/or Refractory View
None Metastatic Cancer View
None Advanced Tumors View
None Hematological cancer View
None Newly diagnosed View